Pharmacological Inhibitors of Mutant Ras: Preclinical Studies, Biomarkers of Response and Rational Design of Combination Regimens. (IMS 2026) - Sep 11, 2026 - Abstract #PA-345; Pres time: Sep 23, 2026; "We thus evaluated the efficacy of inhibitors targeting specific KRAS mutants (e.g., G12C [MRTX-1257]; G12D [MRTX-1133]), a broader spectrum of KRAS mutants (BI-2865), or multiple mutant and wild-type RAS forms (e.g., RMC-6236 and RMC-7977) in preclinical models of MM...Finally, using in vitro pharmacological screening, we identified sensitizers and confirmed in vivo (NSG mice) that RMC-6236 combined with lenalidomide is more active than either agent alone. These findings map the complex molecular landscape underlying Ras inhibitor responses and can inform personalized clinical development of these agents in MM. ( authors with equal contribution)"
Preclinical • Solid Tumor • FGFR3 • IL6 • KRAS • NRAS • PPIA
|
|
Omar Al-Odat1; Torsten Steinbrunn2; Arnold Bolomsky1; Ricardo de Matos Simoes3; Eleni Anastasakou3; Ryosuke Shirasaki4; Michele Ceribelli5; Olga Dashevsky3; Huihui Tang3; Shizuka Yamano3; Oliver Bohorquez3; Vikas A. Gupta6; Jonathan Licht7; Benjamin Barwick6; Lawrence Boise6; Craig J. Thomas5; Constantine S. Mitsiades8; Ryan Young1
|